| Jason Mark Beckta, MD, PHD | |
|
160 Allen St, Rutland, VT 05701-4560 | |
| (802) 747-1831 | |
| Not Available |
| Full Name | Jason Mark Beckta |
|---|---|
| Gender | Male |
| Speciality | Radiation Oncology |
| Experience | 8 Years |
| Location | 160 Allen St, Rutland, Vermont |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295182442 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0001X | Radiology - Radiation Oncology | 308237-01 (New York) | Secondary |
| 2085R0001X | Radiology - Radiation Oncology | 042-0016454 (Vermont) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rutland Regional Medical Center | Rutland, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Vermont Medical Center Inc | 3779491071 | 994 |
News Archive
Scientists have found a new function of the nuclear membrane, the envelope that encases and protects DNA in the nucleus of a cell - it fixes potentially fatal breaks in DNA strands.
Researchers at Linköping University have made a discovery that could contribute to developing new vaccines and treatment alternatives for tuberculosis in the future. The results have been published in Scientific Reports, a sister journal to the highly respected periodical Nature.
Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.
New University of British Columbia research reveals that workers who witness bullying can have a stronger urge to quit than those who experience it firsthand.
› Verified 6 days ago
| Entity Name | University Of Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659309615 PECOS PAC ID: 3779491071 Enrollment ID: O20040406001047 |
News Archive
Scientists have found a new function of the nuclear membrane, the envelope that encases and protects DNA in the nucleus of a cell - it fixes potentially fatal breaks in DNA strands.
Researchers at Linköping University have made a discovery that could contribute to developing new vaccines and treatment alternatives for tuberculosis in the future. The results have been published in Scientific Reports, a sister journal to the highly respected periodical Nature.
Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.
New University of British Columbia research reveals that workers who witness bullying can have a stronger urge to quit than those who experience it firsthand.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jason Mark Beckta, MD, PHD 3035 Route 50 # 1042, Saratoga Springs, NY 12866-2900 Ph: (518) 650-1851 | Jason Mark Beckta, MD, PHD 160 Allen St, Rutland, VT 05701-4560 Ph: (802) 747-1831 |
News Archive
Scientists have found a new function of the nuclear membrane, the envelope that encases and protects DNA in the nucleus of a cell - it fixes potentially fatal breaks in DNA strands.
Researchers at Linköping University have made a discovery that could contribute to developing new vaccines and treatment alternatives for tuberculosis in the future. The results have been published in Scientific Reports, a sister journal to the highly respected periodical Nature.
Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.
New University of British Columbia research reveals that workers who witness bullying can have a stronger urge to quit than those who experience it firsthand.
› Verified 6 days ago
Dr. James N Rademacher, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 160 Allen St, Rutland, VT 05701 Phone: 802-775-7111 | |
Dr. Jed Alan Hummel, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 160 Allen St, Rutland, VT 05701 Phone: 802-747-3650 Fax: 802-747-1754 | |
Daniel Mitchell, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 160 Allen St, Rutland, VT 05701 Phone: 802-747-3650 | |
Dr. Trent W Shelton, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 160 Allen St, Rutland, VT 05701 Phone: 802-747-3650 Fax: 802-747-1754 | |
Andrew Boyer, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 160 Allen St, Rutland, VT 05701 Phone: 802-747-3650 | |
Dr. Richard Dana Lovett, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 160 Allen St, Rutland, VT 05701 Phone: 802-747-1831 Fax: 802-747-1826 |